Form 8-K NANOVIRICIDES, INC. For: Sep 21

NanoViricides (NNVC) Halted Again on LUDP, Up 82%

NanoViricides (NYSE: NNVC) Halted Again on LUDP, Up 82%

NanoViricides (NNVC) Resumes From Halt, Now Halted on LUDP, Up 44%

NanoViricides (NYSE: NNVC) Resumes From Halt, Now Halted on LUDP, Up 44%

NanoViricides (NNVC) Announces Significantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate

(Updated - September 21, 2021 11:29 AM EDT)

NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today on the significant advantages gained by remdesivir encapsulation within its lead COVID-19 candidate NV-CoV-2 thereby producing a potential pan-coronavirus cure, NV-CoV-2-R to finally overcome the current global pandemic.

Pharmacokinetics of Remdesivir

Almost double the remdesivir remained intact in plasma when given as the encapsulated NV-CoV-2-R form, in comparison to the standard remdesivir formulation in SBECD, during... More

NanoViricides (NNVC) was advised that certain articles were published prior to opening of trading by a third party based on certain information that it has not yet publicly released

NanoViricides (NYSE: NNVC)

On September 21, 2021, NanoViricides, Inc. (the Registrant) was advised that certain articles were published, prior to the opening of trading, by a third party based on certain information that the Registrant has not yet publicly released. The third party had received the information confidentially under embargo from our Public Relations provider. The Registrant had advised and confirmed with the third party to extend the embargo in order to provide the Registrants management additional time to review and redraft the document into a... More